Rankings
▼
Calendar
TELO Q4 2024 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$3M
Net Income
-$3M
EPS (Diluted)
$-0.10
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$605,808
Free Cash Flow
-$605,810
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$1M
Total Liabilities
$680,968
Stockholders' Equity
$643,037
Cash & Equivalents
$1M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$3M
-$1M
-169.4%
Net Income
-$3M
-$9M
+68.9%
← FY 2024
All Quarters
Q1 2025 →